cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.f5gpnu
title: Occurrence Download

description: A dataset containing 16895 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((149.171252 -35.380849, 149.177989 -35.380849, 149.177989 -35.378604, 149.182481 -35.378604, 149.182481 -35.367375, 149.191464 -35.367375, 149.191464 -35.365129, 149.19371 -35.365129, 149.19371 -35.360637, 149.195956 -35.360637, 149.195956 -35.356146, 149.198202 -35.356146, 149.198202 -35.351654, 149.195956 -35.351654, 149.195956 -35.349408, 149.19371 -35.349408, 149.19371 -35.344917, 149.189218 -35.344917, 149.189218 -35.340425, 149.19371 -35.340425, 149.19371 -35.335933, 149.198202 -35.335933, 149.198202 -35.340425, 149.195956 -35.340425, 149.195956 -35.342671, 149.211676 -35.342671, 149.211676 -35.340425, 149.204939 -35.340425, 149.204939 -35.335933, 149.202693 -35.335933, 149.202693 -35.329196, 149.19371 -35.329196, 149.19371 -35.333688, 149.189218 -35.333688, 149.189218 -35.335933, 149.186973 -35.335933, 149.186973 -35.342671, 149.180235 -35.342671, 149.180235 -35.340425, 149.16676 -35.340425, 149.16676 -35.344917, 149.164515 -35.344917, 149.164515 -35.349408, 149.162269 -35.349408, 149.162269 -35.351654, 149.155531 -35.351654, 149.155531 -35.344917, 149.157777 -35.344917, 149.157777 -35.342671, 149.162269 -35.342671, 149.162269 -35.335933, 149.157777 -35.335933, 149.157777 -35.340425, 149.15104 -35.340425, 149.15104 -35.344917, 149.148794 -35.344917, 149.148794 -35.342671, 149.144302 -35.342671, 149.144302 -35.344917, 149.139811 -35.344917, 149.139811 -35.349408, 149.142057 -35.349408, 149.142057 -35.351654, 149.144302 -35.351654, 149.144302 -35.356146, 149.142057 -35.356146, 149.142057 -35.358391, 149.133073 -35.358391, 149.133073 -35.360637, 149.148794 -35.360637, 149.148794 -35.365129, 149.144302 -35.365129, 149.144302 -35.367375, 149.139811 -35.367375, 149.139811 -35.371866, 149.142057 -35.371866, 149.142057 -35.374112, 149.15104 -35.374112, 149.15104 -35.378604, 149.155531 -35.378604, 149.155531 -35.374112, 149.162269 -35.374112, 149.162269 -35.383095, 149.171252 -35.383095, 149.171252 -35.380849), (149.164515 -35.358391, 149.16676 -35.358391, 149.16676 -35.365129, 149.164515 -35.365129, 149.164515 -35.367375, 149.171252 -35.367375, 149.171252 -35.380849, 149.16676 -35.380849, 149.16676 -35.374112, 149.164515 -35.374112, 149.164515 -35.371866, 149.157777 -35.371866, 149.157777 -35.367375, 149.155531 -35.367375, 149.155531 -35.365129, 149.157777 -35.365129, 149.157777 -35.360637, 149.164515 -35.360637, 149.164515 -35.358391))"
 ]
}

 The dataset includes 16895 records from 28 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065008-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.26576795
title: Additional file 2 of Application of cardiovascular interventions to decrease blood loss during hepatectomy: a systematic review and meta-analysis

description: Additional file 2: Supplementary Fig. 1. Forest plot of the meta-analysis for the incidence of different types of complications. Supplementary Fig. 2. Forest plot of the meta-analysis for the operating time. Supplementary Fig. 3. Forest plot of the meta-analysis for the perioperative mortality rate. Supplementary Fig. 4. Forest plot of the meta-analysis for the ALT level. ALT, alanine transaminase. Supplementary Fig. 5. Forest plot of the meta-analysis for the AST level. AST, aspartate aminotransferase. Supplementary Fig. 6. Forest plot of the meta-analysis for the total bilirubin level. Supplementary Fig. 7. Forest plot of the meta-analysis for the BUN level. BUN, blood urea nitrogen. Supplementary Fig. 8. Forest plot of the meta-analysis for the Cr level. Cr, creatinine. Supplementary Fig. 9. Forest plot of the meta-analysis for the postoperative hospital stay length.
DOI: 10.6084/m9.figshare.26576795.v1
title: Additional file 2 of Application of cardiovascular interventions to decrease blood loss during hepatectomy: a systematic review and meta-analysis

description: Additional file 2: Supplementary Fig. 1. Forest plot of the meta-analysis for the incidence of different types of complications. Supplementary Fig. 2. Forest plot of the meta-analysis for the operating time. Supplementary Fig. 3. Forest plot of the meta-analysis for the perioperative mortality rate. Supplementary Fig. 4. Forest plot of the meta-analysis for the ALT level. ALT, alanine transaminase. Supplementary Fig. 5. Forest plot of the meta-analysis for the AST level. AST, aspartate aminotransferase. Supplementary Fig. 6. Forest plot of the meta-analysis for the total bilirubin level. Supplementary Fig. 7. Forest plot of the meta-analysis for the BUN level. BUN, blood urea nitrogen. Supplementary Fig. 8. Forest plot of the meta-analysis for the Cr level. Cr, creatinine. Supplementary Fig. 9. Forest plot of the meta-analysis for the postoperative hospital stay length.
DOI: 10.15468/dl.vuhp42
title: Occurrence Download

description: A dataset containing 53005 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Zosteraceae",
 "Year 2010-2020"
 ]
}

 The dataset includes 53005 records from 290 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065009-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.h8u3pa
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "MULTIPOLYGON (((147.686779 -35.394324, 147.686779 -35.403307, 147.69127 -35.403307, 147.69127 -35.394324, 147.686779 -35.394324)), ((147.69127 -35.403307, 147.69127 -35.405553, 147.695762 -35.405553, 147.695762 -35.403307, 147.69127 -35.403307)))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065010-240626123714530/datasets/export for details.
DOI: 10.5517/ccdc.csd.cc2b08j5
title: CCDC 2145216: Experimental Crystal Structure Determination

description: Related Article: C. Döring, P.G. Jones|2024|Acta Crystallogr.,Sect.E:Cryst.Commun.|80|894|doi:10.1107/S2056989024007266
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b08pb
title: CCDC 2145221: Experimental Crystal Structure Determination

description: Related Article: C. Döring, P.G. Jones|2024|Acta Crystallogr.,Sect.E:Cryst.Commun.|80|894|doi:10.1107/S2056989024007266
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b08l7
title: CCDC 2145218: Experimental Crystal Structure Determination

description: Related Article: C. Döring, P.G. Jones|2024|Acta Crystallogr.,Sect.E:Cryst.Commun.|80|894|doi:10.1107/S2056989024007266
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b08rd
title: CCDC 2145223: Experimental Crystal Structure Determination

description: Related Article: C. Döring, P.G. Jones|2024|Acta Crystallogr.,Sect.E:Cryst.Commun.|80|894|doi:10.1107/S2056989024007266
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2b08qc
title: CCDC 2145222: Experimental Crystal Structure Determination

description: Related Article: C. Döring, P.G. Jones|2024|Acta Crystallogr.,Sect.E:Cryst.Commun.|80|894|doi:10.1107/S2056989024007266
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.6084/m9.figshare.26576818
title: A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment

description: <b>Aim:</b> This qualitative study aimed to reveal symptoms and impacts among bone metastatic castration-resistant prostate cancer (or mCRPC) Japanese patients, prior to Radium-223 (Ra-223) treatment. <b>Materials & Methods:</b> Twenty-three mCRPC patients designated to receive Ra-223 and three treating physicians (Ra-223 prescribers) in Japan, were interviewed. All interview data were assessed for concept frequency, themes and saturation. <b>Results:</b> Forty-five percent of the patients (mean age: 75.8 years) were symptomatic at the time of enrollment. Interviews with all patients revealed 47 mCRPC symptoms, including back pain and bone-specific pain, and 45 life impacts, including worry about disease progression and the impact on daily, physical activities. <b>Conclusion:</b> The symptoms and impacts of living with mCRPC and the associated burden of bone metastasis and skeletal-related symptoms are varied and are important considerations for treatment. <b>Aim:</b> This study looked at symptoms and impacts among patients with a type of prostate cancer called metastatic castration-resistant prostate cancer. This cancer has spread to other parts of the body including patients’ bones. Patients’ prostate-specific antigen levels continue to rise despite surgical or medical treatment and their doctors decided the next best treatment is Radium-223 (Ra-223), a radiopharmaceutical therapy. <b>Materials & methods:</b> Twenty-three metastatic castration-resistant prostate cancer patients designated to receive Ra-223 and three treating physicians (Ra-223 prescribers) in Japan, were interviewed. All interview data were assessed for the number of times some words or themes are mentioned by the patients. <b>Results:</b> Ten of the 23 patients (average age of 76 years) had symptoms when the study started. Interviewed patients talked about symptoms including back pain and pain in their bones, and how their cancer caused them to worry about their physical activities and disease progression. <b>Conclusion:</b> The symptoms impact on patients’ daily living and the burden of bone metastasis and bone-related symptoms are varied and are important considerations for treatment. A PDF version of this infographic is available as supplemental material.
DOI: 10.6084/m9.figshare.26576818.v1
title: A qualitative research study in Japan investigating patients’ experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment

description: <b>Aim:</b> This qualitative study aimed to reveal symptoms and impacts among bone metastatic castration-resistant prostate cancer (or mCRPC) Japanese patients, prior to Radium-223 (Ra-223) treatment. <b>Materials & Methods:</b> Twenty-three mCRPC patients designated to receive Ra-223 and three treating physicians (Ra-223 prescribers) in Japan, were interviewed. All interview data were assessed for concept frequency, themes and saturation. <b>Results:</b> Forty-five percent of the patients (mean age: 75.8 years) were symptomatic at the time of enrollment. Interviews with all patients revealed 47 mCRPC symptoms, including back pain and bone-specific pain, and 45 life impacts, including worry about disease progression and the impact on daily, physical activities. <b>Conclusion:</b> The symptoms and impacts of living with mCRPC and the associated burden of bone metastasis and skeletal-related symptoms are varied and are important considerations for treatment. <b>Aim:</b> This study looked at symptoms and impacts among patients with a type of prostate cancer called metastatic castration-resistant prostate cancer. This cancer has spread to other parts of the body including patients’ bones. Patients’ prostate-specific antigen levels continue to rise despite surgical or medical treatment and their doctors decided the next best treatment is Radium-223 (Ra-223), a radiopharmaceutical therapy. <b>Materials & methods:</b> Twenty-three metastatic castration-resistant prostate cancer patients designated to receive Ra-223 and three treating physicians (Ra-223 prescribers) in Japan, were interviewed. All interview data were assessed for the number of times some words or themes are mentioned by the patients. <b>Results:</b> Ten of the 23 patients (average age of 76 years) had symptoms when the study started. Interviewed patients talked about symptoms including back pain and pain in their bones, and how their cancer caused them to worry about their physical activities and disease progression. <b>Conclusion:</b> The symptoms impact on patients’ daily living and the burden of bone metastasis and bone-related symptoms are varied and are important considerations for treatment. A PDF version of this infographic is available as supplemental material.
DOI: 10.6084/m9.figshare.26576812
title: The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma

description: <b>Aim:</b> Sentinel node biopsy is a prognostic indicator of melanoma recurrence. We hypothesized that adding the primary melanoma molecular signature from the 31-gene expression profile (31-GEP) test could refine the risk of recurrence prognosis for patients with stage I–III melanoma. <b>Materials & methods:</b> Four hundred thirty-eight patients with stage I–III melanoma consecutively tested with the 31-GEP were retrospectively analyzed. The 31-GEP stratified patients as low-risk (Class 1A), intermediate-risk (Class 1B/2A) or high risk (Class 2B) of recurrence or metastasis. <b>Results:</b> The 31-GEP significantly stratified patient risk for recurrence-free survival (p &lt; 0.001), distant metastasis-free survival (p &lt; 0.001) and melanoma-specific survival (p &lt; 0.001) and was a significant, independent predictor of metastatic recurrence (hazard ratio: 5.38; p = 0.014). <b>Conclusion:</b> The 31-GEP improves prognostic accuracy in stage I–III melanoma. Cutaneous melanoma is a type of skin tumor affecting 100,000 new patients each year. Even with the best tools available today, knowing which patients will die from their cancer can be challenging. Using individual tumors from over 400 patients, we analyzed the expression of 31 genes from each tumor. Doing this helped us split the patients into groups who are more or less likely to die from their tumor. By combining this technique with current medical practices and guidelines, we hope to help identify which patients may or may not benefit from more intense therapies.
DOI: 10.6084/m9.figshare.26559842.v1
title: Additional file 2 of Splicing factor-mediated regulation patterns reveals biological characteristics and aid in predicting prognosis in acute myeloid leukemia

description: Additional file 2: Table S1. Genes and coefficients of risk score model.
DOI: 10.15468/dl.mkc5zp
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.457707 -35.39657, 147.457707 -35.403307, 147.455462 -35.403307, 147.455462 -35.410045, 147.468936 -35.410045, 147.468936 -35.405553, 147.471182 -35.405553, 147.471182 -35.403307, 147.464445 -35.403307, 147.464445 -35.398816, 147.462199 -35.398816, 147.462199 -35.39657, 147.457707 -35.39657))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065011-240626123714530/datasets/export for details.
DOI: 10.34740/kaggle/dsv/9168919
title: BBC News
DOI: 10.15468/dl.sft67y
title: Occurrence Download

description: A dataset containing 49 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.345417 -35.412291, 147.345417 -35.416782, 147.349909 -35.416782, 147.349909 -35.412291, 147.345417 -35.412291))"
 ]
}

 The dataset includes 49 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065012-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48597/2fbw-76pd
title: Measurement of VOC (hydrocarbons) at Schmücke

description: Measurement of VOC (hydrocarbons) at Schmücke
DOI: 10.48597/uvt8-9gdn
title: VOC (hydrocarbons) at Schmücke

description: Measurement of VOC (hydrocarbons) at Schmücke
DOI: 10.15468/dl.fesaxx
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.572243 -35.412291, 147.572243 -35.416782, 147.576735 -35.416782, 147.576735 -35.412291, 147.572243 -35.412291))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065013-240626123714530/datasets/export for details.
DOI: 10.48597/mwjv-zfm3
title: Measurement of VOC (hydrocarbons) at Zugspitze-Schneefernerhaus

description: Measurement of VOC (hydrocarbons) at Zugspitze-Schneefernerhaus
DOI: 10.48597/5eb3-4tab
title: VOC (hydrocarbons) at Zugspitze-Schneefernerhaus

description: Measurement of VOC (hydrocarbons) at Zugspitze-Schneefernerhaus
DOI: 10.6084/m9.figshare.26559803
title: Additional file 2 of Who’s afraid of the X? Incorporating the X and Y chromosomes into the analysis of DNA methylation array data

description: Additional file 2: Table S2. Extended XY probe annotation for Illumina 450K array.
DOI: 10.6084/m9.figshare.26559806.v1
title: Additional file 3 of Who’s afraid of the X? Incorporating the X and Y chromosomes into the analysis of DNA methylation array data

description: Additional file 3: Table S3. Extended XY probe annotation for Illumina EPIC array.
DOI: 10.48597/gr57-kgbd
title: Measurement of VOC (hydrocarbons) at Zugspitze-Schneefernerhaus

description: Measurement of VOC (hydrocarbons) at Zugspitze-Schneefernerhaus
DOI: 10.15468/dl.66s3bf
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.621651 -35.414536, 147.621651 -35.419028, 147.623897 -35.419028, 147.623897 -35.414536, 147.621651 -35.414536))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065015-240626123714530/datasets/export for details.
DOI: 10.15468/dl.96cvzn
title: Occurrence Download

description: A dataset containing 19890 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is South America",
 "Country is Chile",
 "Geometry POLYGON((-71.6098 -22.08908,-74.4853 -29.08178,-75.13883 -50.58269,-69.73092 -55.9416,-68.60359 -31.89193,-66.83908 -18.69076,-70.95628 -17.05696,-71.6098 -22.08908))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "IucnRedListCategory is LC",
 "OccurrenceStatus is Present",
 "TaxonKey is Tachuris rubrigastra (Vieillot, 1817)"
 ]
}

 The dataset includes 19890 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065017-240626123714530/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.48597/f657-tmxu
title: Measurement of VOC (hydrocarbons) at Neuglobsow

description: Measurement of VOC (hydrocarbons) at Neuglobsow
DOI: 10.48597/kybk-fg57
title: Measurement of VOC (hydrocarbons) at Neuglobsow

description: Measurement of VOC (hydrocarbons) at Neuglobsow
DOI: 10.48597/zfqc-eth4
title: VOC (hydrocarbons) at Zingst

description: Measurement of VOC (hydrocarbons) at Zingst
DOI: 10.48597/udn3-92nf
title: Measurement of VOC (hydrocarbons) at Zingst

description: Measurement of VOC (hydrocarbons) at Zingst
DOI: 10.48597/93yq-f44z
title: VOC (hydrocarbons) at Neuglobsow

description: Measurement of VOC (hydrocarbons) at Neuglobsow
DOI: 10.48597/qtdz-pcea
title: Measurement of VOC (hydrocarbons) at Schmücke

description: Measurement of VOC (hydrocarbons) at Schmücke
DOI: 10.15468/dl.pcjrzb
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((147.455462 -35.419028, 147.455462 -35.421274, 147.457707 -35.421274, 147.457707 -35.419028, 147.455462 -35.419028))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0065019-240626123714530/datasets/export for details.
DOI: 10.48597/nutf-bbx6
title: Measurement of VOC (hydrocarbons) at Zingst

description: Measurement of VOC (hydrocarbons) at Zingst
DOI: 10.6084/m9.figshare.26577053
title: Additional file 6 of Localized microglia dysregulation impairs central nervous system myelination in development

description: Additional file 6: Sheet 5. Proteomic analysis of microglia conditioned media. Average spectral counts and spectral count fraction following treatment with IFNγ/LPS or vehicle control. n = 3 biological replicates per treatment condition.
DOI: 10.6084/m9.figshare.26577053.v1
title: Additional file 6 of Localized microglia dysregulation impairs central nervous system myelination in development

description: Additional file 6: Sheet 5. Proteomic analysis of microglia conditioned media. Average spectral counts and spectral count fraction following treatment with IFNγ/LPS or vehicle control. n = 3 biological replicates per treatment condition.
DOI: 10.6084/m9.figshare.26577059
title: Additional file 8 of Localized microglia dysregulation impairs central nervous system myelination in development

description: Additional file 8: Supplemental Sheet 7. Differentially expressed genes from comparison of iROI-M− to other ROI. Differentially expressed genes (DEGs) in all iROI-M− versus all other ROI (cROI and iROI-M+ combined). N = 6 infants with iROI-M−, 6 infants with cROI, and 4 infants with iROI-M+.
DOI: 10.6084/m9.figshare.26577056.v1
title: Additional file 7 of Localized microglia dysregulation impairs central nervous system myelination in development

description: Additional file 7: Sheet 6. Differentially expressed genes from comparison of injured infants to control infants. Differentially expressed genes (DEGs) and interferon-related DEGs in injured versus control infants. N = 6 control infants, 6 injured infants. FC: fold change.
DOI: 10.6084/m9.figshare.26559803.v1
title: Additional file 2 of Who’s afraid of the X? Incorporating the X and Y chromosomes into the analysis of DNA methylation array data

description: Additional file 2: Table S2. Extended XY probe annotation for Illumina 450K array.